FDA — authorised 6 August 2020
- Application: NDA213464
- Marketing authorisation holder: BAYER HEALTHCARE
- Local brand name: LAMPIT
- Indication: TABLET — ORAL
- Status: approved
🇺🇸 Lampit in United States
FDA authorised Lampit on 6 August 2020
Marketing authorisation
Lampit in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Infectious Disease approved in United States
Frequently asked questions
Is Lampit approved in United States?
Yes. FDA authorised it on 6 August 2020.
Who is the marketing authorisation holder for Lampit in United States?
BAYER HEALTHCARE holds the US marketing authorisation.